AndzonBio2

Andzon Bio is an innovative biotechnology company focused on developing next-generation antibody-based therapeutics for oncology and autoimmune diseases. The company leverages its proprietary multi-specific antibody and antibody-drug conjugate (ADC) platforms to create high-precision biologics that target complex disease mechanisms. Their pipeline includes candidates targeting Claudin 18.2 and immune checkpoints, aiming to provide more effective treatments for hard-to-treat cancers like gastric and pancreatic carcinoma. Andzon Bio operates with a global vision, maintaining research and development facilities to accelerate the transition of its candidates from discovery to clinical trials.